Results 191 to 200 of about 162,947 (233)
High-level amikacin resistance in Pseudomonas aeruginosa associated with a 3′-phosphotransferase with high affinity for amikacin [PDF]
International Journal of Antimicrobial Agents, 2000 This work describes the characterization of the phosphotransferase enzymatic activity responsible for amikacin resistance in two clinical Pseudomona aeruginosa strains, isolated from a hospital that used amikacin as first-line aminoglycoside.
Michael Perlin +2 more
exaly +2 more sources
Frontiers in Microbiology, 2018 Non-tuberculous mycobacteria (NTM) cause pulmonary infections in patients with structural lung damage, impaired immunity, or other risk factors. Delivering antibiotics to the sites of these infections is a major hurdle of therapy because pulmonary NTM ...
Walter R Perkins
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Therapeutic Drug Monitoring, 1985
Amikacin, a semisynthetic analog of kanamycin, is very active against most gram-negative bacteria including gentamicin- and tobramycin-resistant strains. The effectiveness of amikacin in the treatment of serious gram-negative bacillary infections is well documented.
A M, Ristuccia, B A, Cunha
openaire +2 more sources
Amikacin, a semisynthetic analog of kanamycin, is very active against most gram-negative bacteria including gentamicin- and tobramycin-resistant strains. The effectiveness of amikacin in the treatment of serious gram-negative bacillary infections is well documented.
A M, Ristuccia, B A, Cunha
openaire +2 more sources
Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis
Antimicrobial Agents and Chemotherapy, 2018 Practitioners commonly use amikacin in patients with cystic fibrosis. Establishment of the pharmacokinetics of amikacin in adults with cystic fibrosis may increase the efficacy and safety of therapy.
Catherine M Sherwin +2 more
exaly +2 more sources